Abstract
A substantial proportion of breast cancers are large (greator than3 cm) or locally advanced (T 3 , T 4 , TXN 2 ) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.
Keywords: chemotherapeutic agents, induction chemotherapy, breast cancer, T3 T4 TXN2, anthracyclines, doxorubcin, streptomyces, epirubicin, alkylating agents, cyclophosphamide, acrolein, taxoids, paclitaxel Taxol, docetaxel, fluorinated pyrimidines, her 2 NEU THERAPY, endocrine therapy, anti oestrogens, toremifene, ralozifene, selective oestrogen receptor modulators SERMs, faslodex, exemestane, letrozole
Current Pharmaceutical Design
Title: Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer
Volume: 6 Issue: 3
Author(s): Ian C. Smith, Andrew W. Hutcheon and Steven D. Heys
Affiliation:
Keywords: chemotherapeutic agents, induction chemotherapy, breast cancer, T3 T4 TXN2, anthracyclines, doxorubcin, streptomyces, epirubicin, alkylating agents, cyclophosphamide, acrolein, taxoids, paclitaxel Taxol, docetaxel, fluorinated pyrimidines, her 2 NEU THERAPY, endocrine therapy, anti oestrogens, toremifene, ralozifene, selective oestrogen receptor modulators SERMs, faslodex, exemestane, letrozole
Abstract: A substantial proportion of breast cancers are large (greator than3 cm) or locally advanced (T 3 , T 4 , TXN 2 ) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.
Export Options
About this article
Cite this article as:
Smith C. Ian, Hutcheon W. Andrew and Heys D. Steven, Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer, Current Pharmaceutical Design 2000; 6 (3) . https://dx.doi.org/10.2174/1381612003401073
DOI https://dx.doi.org/10.2174/1381612003401073 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity
Mini-Reviews in Medicinal Chemistry Nucleic Acids as Targets for Antitelomerase Agents
Mini-Reviews in Medicinal Chemistry Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry The Asymmetric [C+NC+CC] Coupling Reaction: Development and Application to Natural Product Synthesis
Current Organic Synthesis Nano Traditional Chinese Medicine: Current Progresses and Future Challenges
Current Drug Targets Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Near-Infrared Quantum Dot Contrast Agents for Fluorescence Tissue Imaging: A Phantom Study
Current Nanoscience Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets Cytostatic and Cytotoxic Activity of Synthetic Diterpene Derivatives Obtained from (-)-Kaur-9(11), 16-Dien-19-Oic Acid Against Human Cancer Cell Lines
Letters in Drug Design & Discovery Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery The Yin and Yang of microRNA Assay Methods
MicroRNA Arylsulfonylhydrazone Induced Apoptosis in MDA-MB-231 Breast Cancer Cells
Letters in Drug Design & Discovery Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy A Survey on Machine Learning Algorithms for the Diagnosis of Breast Masses with Mammograms
Current Medical Imaging Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets